Evaluating cancer sequencing for multiple myeloma treatment
Cancer Sequencing Guided Personalized and Precision Medicine Platform in Multiple Myeloma
This study is testing new ways to analyze tumor samples from people with relapsed multiple myeloma to see if it can help find better treatments for them.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Icahn School of Medicine at Mount Sinai Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (New York, New York) |
| Trial ID | NCT06338150 on ClinicalTrials.gov |
What this trial studies
This observational study aims to enhance cancer sequencing techniques to better characterize the molecular makeup of tumors in patients with relapsed multiple myeloma. Over a two-year period, participants will undergo standard tumor biopsies and provide biospecimen samples, including blood and cheek swabs, for comprehensive cancer sequencing analysis. The study will focus on identifying somatic variations and potential novel therapeutics based on the sequencing data. Participants will be recruited through self-referral or physician referral, ensuring a thorough collection of medical histories and informed consent.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with a diagnosis of relapsed multiple myeloma who are undergoing standard biopsy procedures.
Not a fit: Patients with other types of cancer or specific conditions like AL amyloidosis or Waldenstrom Macroglobulinemia may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved personalized treatment options for patients with multiple myeloma.
How similar studies have performed: Other studies utilizing advanced cancer sequencing techniques have shown promise in improving treatment outcomes, suggesting a favorable outlook for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients must be 18 years of age at the time of registration. * Participant must have an established diagnosis of relapsed Multiple Myeloma based on IMWG criteria, be willing to participate, and able to consent * Participant must have a treating physician who agrees to participate in the study * Participant will be undergoing a bone marrow biopsy or tumor biopsy as part of their standard of care. * Patients must be willing to participate in this study and able to sign informed consent. * Participants are not participating in any interventional clinical trial using systemic therapy directed towards control of MM. Exclusion Criteria * Known diagnosis of AL amyloidosis, Waldenstrom Macroglobulinemia, POEMS, or Castleman´s disease. * Diagnosis of cancer other than myeloma or skin cancer (squamous cell or basal cell) that is ongoing or treated within the last 2 years. * Tumor sample inadequate or unavailable for analysis (e.g., due to insufficient number of tumor cells). * Patient will not be receiving systemic MM-directed chemotherapy/immunotherapy in the following 2 months from the time tumor biopsy is performed.
Where this trial is running
New York, New York
- Mount Sinai Health System — New York, New York, United States (Recruiting)
Study contacts
- Principal investigator: Cesar Rodriguez Valdes, MD, PhD — Icahn School of Medicine at Mount Sinai
- Study coordinator: Cesar Rodriguez Valdes, MD, PhD
- Email: Cesar.Rodriguez@mssm.edu
- Phone: (212) 241-7873
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.